Floatz logo

Recaticimab

Atherosclerotic Plaque

Peking Union Medical College HospitalPhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

18 Active assets in the Atherosclerotic Plaque cohort.

Asset / SponsorPhaseRating
Acetylsalicylic Acid
Rajaie Cardiovascular Medical and Research Center
Phase 4BBB
SIMVASTATIN
Northern California Institute of Research and Education
Phase 4BBB
ADVICOR COMPONENT NIACIN
University of Washington
Phase 4BB
Lipitor
Erasmus Medical Center
Phase 4BB
Plavix
Ewha Womans University Seoul Hospital
Phase 4BB

View all 49 →

Same molecule, other indications

Recaticimab is also rated in:

ischemic strokeDormant
BB
Indicative ·
65 / 100
View asset →
cerebral atherosclerosisDormant
BB
Indicative ·
65 / 100
View asset →
non-small cell lung carcinomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →